Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.
Blood
; 115(22): 4393-402, 2010 Jun 03.
Article
in En
| MEDLINE
| ID: mdl-20194898
Full text:
1
Database:
MEDLINE
Main subject:
B-Lymphocytes
/
Antigens, CD20
/
Antibodies, Monoclonal
Type of study:
Prognostic_studies
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
Blood
Year:
2010
Type:
Article
Affiliation country:
Switzerland